Ocugen’s Legal Gambit Aims to Unlock Funding for Gene Therapy Pipeline

A critical legal hearing scheduled for May 6 in Delaware could resolve a major uncertainty hanging over gene therapy developer Ocugen. The company is petitioning the Court of Chancery to validate a controversial increase in its authorized share count, a move designed to nullify a shareholder class action filed last October and secure its future financing strategy.

This legal maneuver comes at a time of stark contrast between Wall Street’s outlook and the stock’s recent performance. While shares have tumbled roughly 25% over the past month to trade near €1.50, analyst sentiment has grown increasingly bullish. The average price target among covering firms now stands at $9.75, with several institutions issuing aggressive upgrades. Lucid Capital leads with a $22 target, followed by Canaccord Genuity and Noble Capital at $12 each, and Oppenheimer and H.C. Wainwright at $10.

The legal dispute centers on a 2024 vote to raise Ocugen’s authorized common shares from 295 million to 390 million. Plaintiffs in the subsequent class action challenged the voting process, particularly concerning the rights of Series C preferred stockholders. By seeking a judicial declaration under Section 205 of Delaware law, Ocugen hopes to retroactively validate this amendment. A favorable ruling would render the lawsuit moot, providing the company with the legal certainty it seeks for its capital structure. Shareholders have until April 16 to file formal statements regarding the proceeding.

Financially, Ocugen has recently bolstered its balance sheet. A direct share placement in January raised $22.5 million, followed by an additional $15 million in March from the exercise of warrants by an institutional investor. This total of $37.5 million in fresh capital extends the company’s financial runway into the first quarter of 2027, alleviating near-term dilution concerns.

Should investors sell immediately? Or is it worth buying Ocugen?

This funding is crucial for advancing Ocugen’s trio of late-stage gene therapy programs. The company’s lead asset, OCU400 for retinitis pigmentosa, has completed patient recruitment for its Phase 3 trial. A rolling Biologics License Application (BLA) submission to the U.S. FDA is planned for the third quarter of 2026. Strategically, the European Medicines Agency has indicated it will accept the U.S. clinical data, potentially opening a second major market with a single dataset.

The other candidates are also progressing. Positive 12-month data from the Phase 2 study for OCU410 in geographic atrophy were released in March. For OCU410ST, targeting Stargardt disease, dosing in the Phase 2/3 trial is complete, with topline results expected in the second quarter of 2027.

The stock’s recent decline has pushed its Relative Strength Index (RSI) to a deeply oversold reading of 13.6, even as the share price maintains a substantial 152% gain year-to-date. The upcoming quarterly report in May will offer investors a detailed look at the operational costs for preparing the OCU400 BLA submission.

The Delaware court’s decision will be pivotal. A positive outcome would grant management the flexibility to finance its late-stage clinical programs without legal overhang. A rejection, however, could trigger a prolonged battle over the company’s existing capital structure, complicating its path forward.